PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/00, 9/70

A1

(11) International Publication Number: **WO 99/58108**

(43) International Publication Date: 18 November 1999 (18.11.99)

(21) International Application Number: PCT/SE99/00823

(22) International Filing Date: 12 May 1999 (12.05.99)

(30) Priority Data:
9801704-9 14 May 1998 (14.05.98) SE

(71) Applicant *(for all designated States except US)*: BIOGLAN AB [SE/SE]; P.O. Box 50310, S-202 13 Malmö (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: LINDAHL, Åke [SE/SE]; Ringduvevägen 50, S-274 33 Skurup (SE). HAGSLÄTT, Håkan [SE/SE]; Flygelvägen 14, S-224 72 Lund (SE). HEIMAN, Catharina [SE/SE]; Kilian Zollsgatan 11A, S-217 56 Malmö (SE). BRYLAND, Rickard [SE/SE]; V. Rönneholmsvägen 60B, S-217 41 Malmö (SE).

(74) Agent: AWAPATENT AB; P.O. Box 45086, S-104 30 Stockholm (SE).

(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: BIOLOGICALLY ACTIVE COMPOSITION

(57) Abstract

The invention relates to a novel biologically active composition which comprises a biologically active agent to be released therefrom, said biologically active agent being dissolved and/or dispersed in a supersaturated state within a carrier, which carrier comprises a liquid and/or solid non-crystalline ester and/or polyester matrix, and where the precipitation of said biologically active agent is substantially, or completely, inhibited therein. Said supersaturated state is obtainable by subjecting one or more carrier starting substance(s) to such chemical reaction(s) that an ester and/or polyester matrix is provided, the biologically active agent being added after said chemical reaction(s) has (have) been completed.